CA-TERIDION
23.5.2019 14:02:12 CEST | Business Wire | Press release
Teridion , the company delivering the only global public cloud-based WAN service , today announced its deep integration with Cisco Meraki MX Security and SD-WAN appliances. The combined solution is a bold new approach to branch networking, delivering the industry-leading Auto VPN and SD-WAN capabilities of Cisco Meraki’s MX appliances with Teridion’s high throughput and low latency public cloud-based WAN service.
For the first time, enterprises can take advantage of a WAN solution that has visibility and control of first, middle, and last mile of the Internet and extends SD-WAN and WAN acceleration beyond enterprise sites to include SaaS applications and enterprise cloud workloads across multiple public cloud providers. Today’s announcement highlights the new, seamless network level integration between Teridion’s high performance cloud WAN service and Cisco Meraki’s easy-to-use Auto VPN routing and high availability capabilities. Enterprise of all sizes can expect real-time applications such as voice and video to see latency improvements of up to 30 percent and file transfer throughput increases of up to 500 percent. As always, the Cisco Meraki and Teridion solution is secured with Cisco’s market-leading security capabilities and managed in the cloud.
The Teridion cloud WAN service is a simple, snap-in integration with Cisco Meraki MX enterprise security and SD-WAN appliances that brings carrier grade Internet and WAN performance to broadband and dedicated Internet access connections. Teridion is available at a fraction of the cost of carrier circuits, and is backed with an SLA. Partners that offer the combined Cisco Meraki and Teridion solution will be able to engage more opportunities and offer a compelling new service to their installed base.
“This news is tremendous validation for the differentiated WAN offering we launched late last year,” said Pejman Roshan, VP of Products and Marketing for Teridion. “We have been working closely with Cisco Meraki on this deep integration, and together the combined solution makes it easy to deploy a secure and high performance WAN that is 100-percent cloud managed. Together, Cisco Meraki and Teridion enable businesses with regional, nationwide, or global WANs to drastically improve the performance of business critical applications, whether they are hosted in corporate data centers, SaaS applications, or deployed across various cloud providers.”
“As enterprises prepare for a cloud-ready application environment, they are laser focused on providing the best application performance for staff and customers in remote locations and branch offices,” said Raviv Levi, director of product management at Cisco Meraki. “The combined Cisco Meraki and Teridion solution offers rich SD-WAN and security capabilities at the WAN edge that are tightly integrated with a high performance and cost-effective WAN service delivered over cost-effective broadband or dedicated Internet access. This brings better reliability and consistency to the enterprise WAN across multiple sites, as well as high performance access to all SaaS applications and cloud workloads.”
Teridion also announced today the general availability of Teridion for Enterprise, the industry’s first solution that eliminates the reliability and performance gap introduced by the reliance on the public Internet middle-mile and exposed by the massive shifts to the cloud and SD-WAN. By tightly integrating with a leading SD-WAN solution such as the Cisco Meraki SD-WAN, Teridion unites centralized cloud management, enterprise-grade security, and ultra-fast WAN performance in a single, tightly integrated offering. As a result, enterprises leverage a solution that is optimized for delivery performance, reliability, control, and visibility end to end across the public Internet.
Teridion’s public cloud-based WAN service is powered by Teridion Curated Routing , an innovative and cloud native approach to routing that draws on the power of deep learning and brings hierarchical and centralized routing to enterprise networking. Teridion Curated Routing radically improves WAN, application, and SaaS performance. Originally launched delivering interoperability with today’s most popular SD-WAN offerings, today’s announcement marks the first deep, end-to-end integration with a leading SD-WAN solution.
Learn more about Teridion’s deep integration with Cisco Meraki in the Cisco Meraki Marketplace at https://apps.meraki.io/details/teridion-for-enterprise/ , or at teridion.com/meraki .
Availability and Pricing
Teridion for Cisco Meraki is available today from authorized Teridion resellers. Pricing starts at $50 per site per month. More details about how to buy can be found at https://www.teridion.com/meraki .
About Teridion
Founded in 2013, Teridion enables faster and more reliable Internet with Teridion Curated Routing, radically improving Internet performance up to 2X - 20X, anywhere in the world. Teridion for Enterprise combines the performance, reliability, and SLAs of legacy WAN technologies such as MPLS with the agility and elastic scalability of the cloud. The company is backed by leading venture investors including Jerusalem Venture Partners, Magma Venture Partners and Singtel Innov8, and is relied on by leading SaaS providers such as Atlassian, Box, Egnyte, Merrill Corp., and many others. Teridion is headquartered in San Francisco, with international offices in Petah Tikva, Israel. For more information, visit www.teridion.com or email info@teridion.com .
Teridion is a registered trademark of Teridion in the United States and other countries. All rights reserved. All other company and product names are either trademarks or registered trademarks of their respective companies.
View source version on businesswire.com: https://www.businesswire.com/news/home/20190523005161/en/
Contact:
Dan Spalding dspalding@teridion.com (408) 960-9297
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
2PointZero Group Signals Global Scale With Revenue Surge to AED 21.9 Billion and Net Profit of AED 7.7 Billion in H1 202631.7.2026 13:42:00 CEST | Press release
Group revenue growth supported by stable gross profit margin of 29%, and adjusted EBITDA of AED 5.0 billionGlobal expansion milestones include the completed sale of TAQA stake, and the acquisition of Traverse Midstream Partners in North America, Baobab Group in Africa, and 60.8% of ISEM in ItalyTIME ranks the Group 36th on the World’s Growth Leaders list for 2026, highlighting market stability, operational scale and disciplined approach to capital 2PointZero Group (ADX: 2POINTZERO), a leading Abu Dhabi-based investment holding firm, announced its financial results for the first half of 2026, reporting revenue of AED 21.9 billion and delivering a Group Net Profit of AED 7.7 billion. This robust performance is reflected in the Group’s adjusted EBITDA, which reached AED 5.0 billion after excluding fair value changes and one-offs. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260731538982/en/ Samia Bouazza, CEO of 2PointZero (P
Datroway® Approved in the EU as Only TROP2 Directed Medicine with Overall Survival Benefit for the First-Line Treatment of Patients with Metastatic TNBC Who Are Not Candidates for Immunotherapy31.7.2026 08:30:00 CEST | Press release
Approval based on TROPION-Breast02 phase 3 trial results where Daiichi Sankyo and AstraZeneca’s Datroway showed a statistically significant and clinically meaningful improvement for the dual primary endpoints of overall survival and progression-free survival Datroway now approved for two breast cancer indications in the EU Datroway® (datopotamab deruxtecan) has been approved in the European Union (EU) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. Datroway is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The approval by the European Commission follows the positive opinionof the Committee for Medicinal Products for Human Use of the European Medicines Agency and is based on result
Polpharma Biologics Announces FDA and EMA Acceptance for Review of PB016 Vedolizumab Biosimilar Candidate31.7.2026 08:30:00 CEST | Press release
Polpharma Biologics International AG today announces that the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) have accepted for review the Biologics License Application (BLA) and Marketing Authorisation Application (MAA), respectively, for PB016, a proposed vedolizumab biosimilar candidate to Takeda’s reference product Entyvio®* (vedolizumab) lyophilized vial for intravenous (IV) administration for the treatment of adults with moderately to severely active ulcerative colitis and Crohn's disease. The BLA and MAA acceptances represent significant milestones in Polpharma Biologics' development program and underscore the company's commitment to advancing high-quality biosimilars and expanding global access to affordable biologic medicines. "FDA and EMA acceptances for review of our IV vedolizumab biosimilar candidate mark a major achievement for Polpharma Biologics and validate our deep scientific expertise in biosimilar development and manufacturing," said
SES: Disclosure of Share Buyback Transactions31.7.2026 07:30:00 CEST | Press release
In the time period from June 2, 2026 until and including June 23, 2026, a number of 213,167 shares were bought back within the framework of the share buyback of SES to meet obligations under SES’s Equity Based Compensation Plan (EBCP). Shares were bought back as follows: Day of purchase Aggregated volume in shares Daily weighted average acquisition price of shares (EUR) Market June 2, 2026 27,097 8.8727 DXE June 2, 2026 72,903 8.8556 ENX June 5, 2026 16,624 8.3723 DXE June 5, 2026 31,510 8.4266 ENX June 15, 2026 26,451 7.8423 XPAR June 17, 2026 26,812 7.3910 XPAR June 23, 2026 11,770 7.2200 XPAR The transactions in a detailed form are published on SES’s website: https://www.ses.com/investors/shareholder-information/share-buy-backs. Follow us on: Twitter | Facebook | YouTube | LinkedIn | Instagram Read our Blogs > Visit the Media Gallery > About SES At SES, we believe that space has the power to make a difference. That’s why we design space solutions that help governments protect, busin
Half-Year Report on SES’s Liquidity Contract31.7.2026 07:30:00 CEST | Press release
Pursuant to the liquidity contract entered into by SES with BNP Paribas as of 7 April 2026, please see the below update on the progress of the liquidity services. When the liquidity services were implemented as of 7 April 2026, the following assets were in the liquidity account: € 2,500,000 As of 30 June 2026, the following assets appeared on the liquidity account: 228,186 shares; € 816,880. Over the period from 7 April 2026 to 30 June 2026, the following transactions were executed: 1,082 buy transactions; 1,308 sales transactions. Over this same period, the volumes traded represented: 1,093,335 shares and € 8,485,986 on the buy side; 873,399 shares and € 6,860,843 on the sell side. Follow us on: LinkedIn | Facebook | YouTube | X | Instagram Read our Blogs > Visit the Media Gallery > About SES At SES, we believe that space has the power to make a difference. That’s why we design space solutions that help governments protect, businesses grow, and people stay connected—no matter where th
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom